Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) received a drug registration certificate from China's National Medical Products Administration to market Reglitin-Metformin Tablets (I)/(II), according to a Shanghai Stock Exchange filing on Thursday.
The drug is indicated to improve glycemic control in adult patients with type 2 diabetes, who are suitable for treatment with phosphate reglitin and metformin hydrochloride.
This product is China's first independently developed fixed-dose combination formulation of a dipeptidyl peptidase-4 inhibitor with metformin, the disclosure said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.